Menopause HRT bleeding: what is and isn’t normal. - Reddit

Why does HRT cause bleeding or spotting?

Hormone replacement therapy works by replenishing estrogen — and in women with a uterus, progestogen — that declines during and after menopause. Estrogen stimulates the growth of the uterine lining (endometrium); progestogen counteracts that stimulation and triggers the lining to shed or stabilize.

This hormonal push-and-pull is why bleeding on HRT happens. The uterine lining is responding to the hormones it is receiving, and the pattern of bleeding reflects the specific regimen in use. Different types of HRT are deliberately designed with different bleeding outcomes in mind.

What are the three main HRT regimen types and their bleeding profiles?

Sequential (cyclical) HRT

In sequential HRT, estrogen is taken continuously and progestogen is added for 10–14 days each month or every three months. This approach is designed to produce a scheduled withdrawal bleed when progestogen is stopped or withdrawn — similar in timing to a menstrual period. This regimen is often preferred for women who are perimenopausal or who have been postmenopausal for less than a year.

Breakthrough bleeding between the scheduled bleeds is less expected and should be reported to a clinician, particularly if it is heavy or recurrent.

Continuous combined HRT

Continuous combined HRT delivers estrogen and progestogen every day without a break. The intent is to suppress the endometrium continuously so that no withdrawal bleed occurs. For most women, this results in no regular bleeding after an initial adjustment period.

However, irregular spotting and light breakthrough bleeding in the first 3–6 months of continuous combined HRT is extremely common and expected. The uterine lining takes time to settle into continuous suppression. Most women experience decreasing spotting through this period and none after the first six months.

Estrogen-only HRT

Estrogen-only HRT is only appropriate for women who have had a hysterectomy — because estrogen alone stimulates endometrial growth, which carries risk in women with a uterus. Women on estrogen-only HRT should not experience uterine bleeding; any bleeding in this context requires evaluation.

What counts as normal breakthrough bleeding on HRT

Within the context of continuous combined HRT, these patterns are generally considered within the expected adjustment range:

• Light spotting (brown or pink discharge) in the first 3–6 months of starting a new continuous combined regimen
• Irregular light bleeding that is decreasing in frequency and volume over time
• Brief spotting after a dose or formulation change — the uterine lining is readjusting

These patterns typically resolve on their own as the uterine lining stabilizes. Your clinician should know about them anyway — they are part of the monitoring picture for HRT management.

What HRT bleeding requires a clinician evaluation?

Not all HRT bleeding is an expected side effect. These patterns warrant prompt contact with your clinician:

• Heavy bleeding (soaking a pad per hour for two or more consecutive hours)
• Resumption of regular bleeding after 12 or more months of no bleeding on continuous combined HRT
• Bleeding that persists past 6 months of starting continuous combined HRT without decreasing
• Bleeding accompanied by pelvic pain, pressure, or unusual discharge
• Any new bleeding in women who are postmenopausal and not on HRT — this is never expected and always warrants investigation

The concern with unexplained postmenopausal bleeding — particularly in women on continuous HRT who have passed the adjustment period — is endometrial changes, including endometrial hyperplasia. This is a manageable, treatable condition when caught early, but early evaluation is key.

How does the bleeding evaluation work?

When abnormal or unexpected bleeding is reported, a clinician will typically consider:

• Transvaginal ultrasound to assess endometrial thickness — a thickened lining can indicate overstimulation
• Endometrial biopsy if the ultrasound shows concerning thickness or if bleeding is recurrent
• HRT regimen review — progestogen dose, formulation, or delivery method may need adjustment
• Hysteroscopy in cases where fibroids, polyps, or other structural factors are suspected

This is not a workup to fear — it is routine monitoring for any woman on long-term hormone therapy. The goal is making sure the progestogen component of HRT is adequately protecting the endometrium.

Progestogen choice and bleeding outcomes

The specific progestogen used in HRT, and how it is delivered, substantially affects bleeding patterns. Key options include:

• Oral micronized progesterone — considered bioidentical; may produce less breakthrough bleeding than synthetic progestins in some women
• Norethisterone / norethindrone — a synthetic progestogen common in combined pills and patches; effective but associated with more bleeding variability
• Levonorgestrel-releasing IUS (e.g. Mirena) — local progestogen delivery that provides excellent endometrial protection with very low systemic exposure and typically minimal bleeding after insertion adjustment
• Dydrogesterone — a progestogen with a receptor profile associated with lower rates of breakthrough bleeding in some European trials

Progestogen selection is a nuanced clinical decision that takes into account bleeding preferences, cardiovascular risk profile, mood-related considerations, and whether a woman prefers systemic or local delivery. This is exactly the kind of individualized decision that clinician-supervised HRT is designed to navigate.

Frequently asked questions